Phoenix Biotech Acquisition (PBAX) Short Interest Ratio & Short Volume

Short interest is the volume of Phoenix Biotech Acquisition shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 800 shares of PBAX short. 0.08% of Phoenix Biotech Acquisition's shares are currently sold short. Learn More on Phoenix Biotech Acquisition's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.08% of Phoenix Biotech Acquisition's floating shares are currently sold short.

Phoenix Biotech Acquisition saw a drop in short interest in January. As of January 31st, there was short interest totaling 800 shares, a drop of 69.2% from the previous total of 2,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Phoenix Biotech Acquisition currently has issued a total of 6,250,000 shares. Some of Phoenix Biotech Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Phoenix Biotech Acquisition currently has a public float of 950,000 shares.

0.08% of Phoenix Biotech Acquisition's shares are currently sold short. Here is how the short interest of companies in the industry of "holding & other investment offices" compare to Phoenix Biotech Acquisition: Plum Acquisition Corp. III (0.02%), Zalatoris Acquisition Corp. (0.00%), Concord Acquisition Corp II (0.00%), Papaya Growth Opportunity Corp. I (0.01%), Direct Selling Acquisition Corp. (0.00%), Integrated Rail and Resources Acquisition Corp. (0.00%), Global Lights Acquisition Corp (0.29%), Evergreen Co. (0.02%), byNordic Acquisition Co. (0.13%), Investcorp India Acquisition Corp (0.02%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors Company ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Corporation ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply Company ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

Short selling PBAX is an investing strategy that aims to generate trading profit from Phoenix Biotech Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Phoenix Biotech Acquisition occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PBAX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PBAX, twice per month. The most recent reporting period available is January, 31 2024.